Extending to human samples, Bu et al. validated the expression of B-cell maturation antigen (BCMA) as a target for CAR-T cell immunotherapy in multiple myeloma [74] while O’ Rourke et al. tracked infused CAR-modified T cells against glioblastoma using RNAscope [75]. Here, TNFRSF17 is linked to glioblastoma.